TScan Therapeutics, Inc. (TCRX) financial statements (2022 and earlier)

Company profile

Business Address 830 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments161,405
Cash and cash equivalents161,405
Other undisclosed current assets4,249
Total current assets:165,654
Noncurrent Assets
Operating lease, right-of-use asset5,491
Property, plant and equipment11,765
Deposits noncurrent assets166
Restricted cash and investments5,031
Total noncurrent assets:22,453
TOTAL ASSETS:188,107
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,326
Accounts payable1,765
Accrued liabilities1,961
Employee-related liabilities2,600
Deferred revenue11,410
Other undisclosed current liabilities3,607
Total current liabilities:21,343
Noncurrent Liabilities
Long-term debt and lease obligation4,392
Operating lease, liability4,392
Liabilities, other than long-term debt1,594
Deferred revenue1,497
Other liabilities97
Total noncurrent liabilities:5,986
Total liabilities:27,329
Stockholders' equity
Stockholders' equity attributable to parent, including:160,778
Additional paid in capital252,933
Accumulated deficit(92,158)
Other undisclosed stockholders' equity attributable to parent3
Total stockholders' equity:160,778
TOTAL LIABILITIES AND EQUITY:188,107

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues10,141
Gross profit:10,141
Operating expenses(58,782)
Operating loss:(48,641)
Loss before gain (loss) on sale of properties:(48,641)
Other undisclosed net income16
Net loss available to common stockholders, diluted:(48,625)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(48,625)
Comprehensive loss, net of tax, attributable to parent:(48,625)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: